Cardiac pharmacological preconditioning with volatile anesthetics: From bench to bedside?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 5 55-5, 2004, Pages

  Riess, Matthias L ^a,d   Stowe, David F ^a,b,c   Warltier, David C ^a,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Medical College of Wisconsin and Marquette University   (United States)

^c CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Age; Clinical; Diabetes; Duration; Ischemia reperfusion injury

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; CYCLOOXYGENASE 2 INHIBITOR; DESFLURANE; GLIBENCLAMIDE; INHALATION ANESTHETIC AGENT; ISOFLURANE; ORAL ANTIDIABETIC AGENT; POTASSIUM CHANNEL BLOCKING AGENT; PROTEIN KINASE C INHIBITOR; REACTIVE OXYGEN METABOLITE; SEVOFLURANE; SULFONYLUREA DERIVATIVE;

AGING; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG CHOICE; DRUG MECHANISM; DRUG WITHDRAWAL; HEART INFARCTION; HEART INFARCTION PREVENTION; HIGH RISK PATIENT; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME;

AGING; ANESTHETICS, INHALATION; ANIMALS; DIABETES MELLITUS; DIFFUSION OF INNOVATION; HEART; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL;

EID: 1942437496     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00963.2003     Document Type: Review

References (73)

1. Abete P, Ferrara N, Cacciatore F, Madrid A, Bianco S, Calabrese C, Napoli C, Scognamiglio P, Bollella O, Cioppa A, Longobardi G, and Rengo F. Angina-induced protection against myocardial infarction in adult and elderly patients: a loss of preconditioning mechanism in the aging heart? J Am Coll Cardiol 30: 947-954, 1997.
2. Badner NH, Knill RL, Brown JE, Novick TV, and Gelb AW. Myocardial infarction after noncardiac surgery. Anesthesiology 88: 572-578, 1998.
3. Belhomme D, Peynet J, Louzy M, Launay JM, Kitakaze M, and Menasche P. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 100: II340-344, 1999.
4. Bonventre JV. Kidney ischemic preconditioning. Curr Opin Nephrol Hypertens 11: 43-48, 2002.
5. Cason BA, Gamperl AK, Slocum RE, and Hickey RF. Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocardial infarct size in rabbits. Anesthesiology 87: 1182-1190, 1997.
6. Cope DK, Impastato WK, Cohen MV, and Downey JM. Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology 86: 699-709, 1997.
7. De Hert S, Turani F, Mathur S, and Stowe DF. Cardioprotection with volatile anesthetics-mechanism and clinical implications. Anesth Analg. In press.
8. Dirnagl U, Simon RP, and Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 26: 248-254, 2003.
9. Ebel D, Müllenheim J, Frassdorf J, Heinen A, Huhn R, Bohlen T, Ferrari J, Sudkamp H, Preckel B, Schlack W, and Thamer V. Effect of acute hyperglycaemia and diabetes mellitus with and without short-term insulin treatment on myocardial ischaemic late preconditioning in the rabbit heart in vivo. Pflügers Arch 446: 175-182, 2003.
10. Eckenhoff RG and Johansson JS. Molecular interactions between inhaled anesthetics and proteins. Pharmacol Rev 49: 343-367, 1997.
11. Freedman BM, Hamm DP, Everson CT, Wechsler AS, and Christian CM 2nd. Enflurane enhances postischemic functional recovery in the isolated rat heart. Anesthesiology 62: 29-33, 1985.
12. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, and Ma XL. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105: 1497-1502, 2002.
13. Grover GJ and Garlid KD. ATP-sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol 32: 677-695, 2000.
14. Gu W, Pagel PS, Warltier DC, and Kersten JR. Modifying cardiovascular risk in diabetes mellitus. Anesthesiology 98: 774-779, 2003.
15. Harkin CP, Pagel PS, Kersten JR, Hettrick DA, and Warltier DC. Direct negative inotropic and lusitropic effects of sevoflurane. Anesthesiology 81: 156-167, 1994.
16. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, Kouno Y, Umemura T, Nakamura S, and Sato H. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 38: 1007-1011, 2001.
17. Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, Chassot PG, Schmid ER, Turina MI, von Segesser LK, Pasch T, Spahn DR, and Zaugg M. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology 98: 1315-1327, 2003.
18. Kapinya KJ, Lowl D, Futterer C, Maurer M, Waschke KF, Isaev NK, and Dirnagl U. Tolerance against ischemic neuronal injury can be induced by volatile anesthetics and is inducible NO synthase dependent. Stroke 33: 1889-1898, 2002.
19. Kehl F, Krolikowski JG, Mraovic B, Pagel PS, Warltier DC, and Kersten JR. Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology 96: 183-188, 2002.
20. Kehl F, Krolikowski JG, Mraovic B, Pagel PS, Warltier DC, and Kersten JR. Is isoflurane-induced preconditioning dose related? Anesthesiology 96: 675-680, 2002.
21. Kehl F, Pagel PS, Krolikowski JG, Gu W, Toller W, Warltier DC, and Kersten JR. Isoflurane does not produce a second window of preconditioning against myocardial infarction in vivo. Anesth Analg 95: 1162-1168, 2002.
22. Kersten JR, Schmeling TJ, Orth KG, Pagel PS, and Warltier DC. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol Heart Circ Physiol 275: H721-H725, 1998.
23. ATP channels: reduction of myocardial infarct size with an acute memory phase. Anesthesiology 87: 361-370, 1997.
24. Kevin LG, Katz P, Camara AK, Novalija E, Riess ML, and Stowe DF. Anesthetic preconditioning: effects on latency to ischemic injury in isolated hearts. Anesthesiology 99: 385-391, 2003.
25. Kevin LG, Novalija E, Riess ML, Camara AK, Rhodes SS, and Stowe DF. Sevoflurane exposure generates superoxide but leads to decreased superoxide during ischemia and reperfusion in isolated hearts. Anesth Analg 96: 949-955, 2003.
26. Kissin I, Aultman DF, and Smith LR. Effects of volatile anesthetics on myocardial oxidation-reduction status assessed by NADH fluorometry. Anesthesiology 59: 447-452, 1983.
27. Koti RS, Seifalian AM, and Davidson BR. Protection of the liver by ischemic preconditioning: a review of mechanisms and clinical applications. Dig Surg 20: 383-396, 2003.
28. + channel of heart mitochondria. Am J Physiol Heart Circ Physiol 280: H649-H657, 2001.
29. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, and Tada M. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 72: 1293-1299, 1993.
30. Kwok WM, Martinelli AT, Fujimoto K, Suzuki A, Stadnicka A, and Bosnjak ZJ. Differential modulation of the cardiac adenosine triphosphate-sensitive potassium channel by isoflurane and halothane. Anesthesiology 97: 50-56, 2002.
31. Loubani M, Ghosh S, and Galinanes M. The aging human myocardium: tolerance to ischemia and responsiveness to ischemic preconditioning. J Thorac Cardiovasc Surg 126: 143-147, 2003.
32. Mangano DT, Wong MG, London MJ, Tubau JF, and Rapp JA. Perioperative myocardial ischemia in patients undergoing noncardiac surgery. II: incidence and severity during the 1st week after surgery. The Study of Perioperative Ischemia (SPI) Research Group. J Am Coll Cardiol 17: 851-857, 1991.
33. Matsumoto M, Yamaguchi M, Hashiguchi H, Morooka H, and Sumikawa K. Isoflurane inhibits NFkB activation in response to simulated ischemia in renal tubular cell line, LLC-PK1. Anesthesiology 99: A1545, 2003.
34. Mitchell P. Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. Biol Rev Camb Philos Soc 41: 445-502, 1966.
35. Mraovic B, Krolikowski J, Pagel P, Warltier D, and Kersten J. Role of cyclooxygenase during ischemic and pharmacological preconditioning in dogs. Anesthesiology 99: A1539, 2003.
36. Müllenheim J, Ebel D, Frassdorf J, Preckel B, Thamer V, and Schlack W. Isoflurane preconditions myocardium against infarction via release of free radicals. Anesthesiology 96: 934-940, 2002.
37. Murry CE, Jennings RB, and Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986.
38. Novalija E, Kevin LG, Camara AK, Bosnjak ZJ, Kampine JP, and Stowe DF. Reactive oxygen species precede the epsilon isoform of protein kinase C in the anesthetic preconditioning signaling cascade. Anesthesiology 99: 421-428, 2003.
39. Novalija E, Varadarajan SG, Camara AK, An J, Chen Q, Riess ML, Hogg N, and Stowe DF. Anesthetic preconditioning: triggering role of reactive oxygen and nitrogen species in isolated hearts. Am J Physiol Heart Circ Physiol 283: H44-H52, 2002.
40. Okubo S, Xi L, Bernardo NL, Yoshida K, and Kukreja RC. Myocardial preconditioning: basic concepts and potential mechanisms. Mol Cell Biochem 196: 3-12, 1999.
41. Piriou V, Chiari P, Knezynski S, Bastien O, Loufoua J, Lehot JJ, Foex P, Annat G, and Ovize M. Prevention of isoflurane-induced preconditioning by 5-hydroxydecanoate and gadolinium: possible involvement of mitochondrial adenosine triphosphate-sensitive potassium and stretch-activated channels. Anesthesiology 93: 756-764, 2000.
42. Riess ML, Camara AK, Chen Q, Novalija E, Rhodes SS, and Stowe DF. Altered NADH and improved function by anesthetic and ischemic preconditioning in guinea pig intact hearts. Am J Physiol Heart Circ Physiol 283: H53-H60, 2002.
43. Riess ML, Eells JT, Kevin LG, Camara AKS, Henry MM, and Stowe DF. Attenuation of mitochondrial respiration by sevoflurane in isolated cardiac mitochondria is mediated in part by reactive oxygen species. Anesthesiology 100: 498-505, 2003.
44. Riess ML, Kevin LG, Camara AKS, Heisner JS, and Stowe DF. Dual brief exposure more than single long exposure to sevoflurane determines degree of anesthetic preconditioning. Anesthesiology 100: 569-574, 2003.
45. Riess ML, Novalija E, Camara AK, Eells JT, Chen Q, and Stowe DF. Preconditioning with sevoflurane reduces changes in nicotinamide adenine dinucleotide during ischemia-reperfusion in isolated hearts: reversal by 5-hydroxydecanoic acid. Anesthesiology 98: 387-395, 2003.
46. 1 receptors and adenosine triphosphate-sensitive potassium channels. Anesthesiology 92: 1692-1701, 2000.
47. Ross S and Foex P. Protective effects of anaesthetics in reversible and irreversible ischaemia-reperfusion injury. Br J Anaesth 82: 622-632, 1999.
48. Sandhu R, Diaz RJ, Mao GD, and Wilson GJ. Ischemic preconditioning: differences in protection and susceptibility to blockade with single-cycle versus multicycle transient ischemia. Circulation 96: 984-995, 1997.
49. Schulman D, Latchman DS, and Yellon DM. Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 281: H1630-H1636, 2001.
50. Shen YT and Vatner SF. Differences in myocardial stunning following coronary artery occlusion in conscious dogs, pigs, and baboons. Am J Physiol Heart Circ Physiol 270: H1312-H1322, 1996.
51. Slogoff S and Keats AS. Randomized trial of primary anesthetic agents on outcome of coronary artery bypass operations. Anesthesiology 70: 179-188, 1989.
52. Sniecinski R and Liu H. Reduced efficacy of volatile anesthetic preconditioning with advanced age in isolated rat myocardium. Anesthesiology 100: 589-597, 2003.
53. Stowe DF and Kevin LG. Cardiac preconditioning by volatile anesthetic agents: a defining role for altered mitochondrial bioenergetics. Antioxidants and Redox Signaling 602: 439-448, 2004.
54. Tanaka K, Kehl F, Gu W, Krolikowski JG, Pagel PS, Warltier DC, and Kersten JR. Isoflurane-induced preconditioning is attenuated by diabetes. Am J Physiol Heart Circ Physiol 282: H2018-H2023, 2002.
55. Tanaka K, Ludwig LM, Kersten JR, Pagel PS, and Warltier DC. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 100: 707-721, 2003.
56. Tanaka K, Ludwig LM, Krolikowski JG, Alcindor D, Pratt PF, Kersten JR, Pagel PS, and Waritier DC. Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. Anesthesiology 100: 525-531, 2003.
57. Tanaka K, Weihrauch D, Kehl F, Ludwig LM, LaDisa JF Jr, Kersten JR, Pagel PS, and Warltier DC. Mechanism of preconditioning by isoflurane in rabbits: a direct role for reactive oxygen species. Anesthesiology 97: 1485-1490, 2002.
58. Tarnow J, Markschies-Hornung A, and Schulte-Sasse U. Isoflurane improves the tolerance to pacing-induced myocardial ischemia. Anesthesiology 64: 147-156, 1986.
59. Taylor RP and Starnes JW. Age, cell signalling and cardioprotection. Acta Physiol Scand 178: 107-116, 2003.
60. Toller WG, Gross ER, Kersten JR, Pagel PS, Gross GJ, and warltier DC. Sarcolemmal and mitochondrial adenosine triphosphate-dependent potassium channels: mechanism of desflurane-induced cardioprotection. Anesthesiology 92: 1731-1739, 2000.
61. Toller WG, Kersten JR, Gross ER, Pagel PS, and Warltier DC. Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins. Anesthesiology 92: 1400-1407, 2000.
62. Toller WG, Montgomery MW, Pagel PS, Hettrick DA, Warltier DC, and Kersten JR. Isoflurane-enhanced recovery of canine stunned myocardium: role for protein kinase C? Anesthesiology 91: 713-722, 1999.
63. Tonkovic-Capin M, Gross GJ, Bosnjak ZJ, Tweddell JS, Fitzpatrick CM, and Baker JE. Delayed cardioprotection by isoflurane: role of KATP channels. Am J Physiol Heart Circ Physiol 283: H61-H68, 2002.
64. Tuman KJ, McCarthy RJ, Spiess BD, DaValle M, Dabir R, and Ivankovich AD. Does choice of anesthetic agent significantly affect outcome after coronary artery surgery? Anesthesiology 70: 189-198, 1989.
65. Uecker M, Da Silva R, Grampp T, Pasch T, Schaub MC, and Zaugg M. Translocation of protein kinase C isoforms to subcellular targets in ischemic and anesthetic preconditioning. Anesthesiology 99: 138-147, 2003.
66. Van Der Linden PJ, Daper A, Trenchant A, and De Hert SG. Cardioprotective effects of volatile anesthetics in cardiac surgery. Anesthesiology 99: 516-517, 2003.
67. Warltier DC, al-Wathiqui MH, Kampine JP, and Schmeling WT. Recovery of contractile function of stunned myocardium in chronically instrumented dogs is enhanced by halothane or isoflurane. Anesthesiology 69: 552-565, 1988.
68. Yellon DM and Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83: 1113-1151, 2003.
69. Yvon A, Hanouz JL, Haelewyn B, Terrien X, Massetti M, Babatasi G, Khayat A, Ducouret P, Bricard H, and Gerard JL. Mechanisms of sevoflurane-induced myocardial preconditioning in isolated human right atria in vitro. Anesthesiology 99: 27-33, 2003.
70. Zaugg M, da Silva M, Sergeev P, Pasch T, and Schaub M. Unravelling the gene expression patterns in ischemic and anesthetic preconditioning by gene chip analysis (Abstract). Anesthesiology 99: A1544, 2003.
71. Zaugg M, Lucchinetti E, Garcia C, Pasch T, Spahn DR, and Schaub MC. Anaesthetics and cardiac preconditioning. Part II. Clinical implications. Br J Anaesth 91: 566-576, 2003.
72. ATP channels via multiple signaling pathways. Anesthesiology 97: 4-14, 2002.
73. Zaugg M, Lucchinetti E, Uecker M, Pasch T, and Schaub MC. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. Br J Anaesth 91: 551-565, 2003.